Business Segments Bio-Thera Solutions, Ltd.
Equities
688177
CNE100003R98
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.07 CNY | +2.08% |
|
+2.26% | -0.30% |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
Biopharmaceutical | 183M | 837M | 455M | 705M | 743M | ||||
Total Assets | 2.39B | 2.62B | 2.18B | 2.29B | 2.21B | ||||
Interest Expense | -3.7M | -775K | -61.93K | -10.38M | -20.55M | ||||
Income Tax Expense | - | 9.11M | 2.12K | 108K | - | ||||
CAPEX | -253M | -77.89M | -259M | -262M | -127M | ||||
EBT | -513M | 91.04M | -480M | -394M | -510M | ||||
D&A | 58.51M | 72.06M | 82.58M | 84.01M | 87.86M | ||||
Operating Income | -514M | 117M | -463M | -390M | -508M | ||||
Net Income | -513M | 81.94M | -480M | -395M | -510M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
China | 183M | 647M | 446M | 684M | 673M | ||||
Interest Expense | -3.7M | - | - | - | - | ||||
D&A | 58.51M | - | - | - | - | ||||
Total Assets | 2.39B | - | - | - | - | ||||
CAPEX | -253M | - | - | - | - | ||||
Net Income | -513M | - | - | - | - | ||||
EBT | -513M | - | - | - | - | ||||
Operating Income | -514M | - | - | - | - | ||||
Overseas | - | - | 9.37M | 20.61M | 69.9M | ||||
USA | - | 1.92M | - | - | - | ||||
Switzerland | - | 188M | - | - | - |
- Stock Market
- Equities
- 688177 Stock
- Financials Bio-Thera Solutions, Ltd.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
